Senior Director, Consumer Marketing, Pulmonary –US

Commercial Cambridge, MA


Description

Who are we?

Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Acceleron’s leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.

Acceleron focuses its commercialization, research, and development efforts in hematologic and pulmonary diseases. In hematology, REBLOZYL® (luspatercept-aamt) is the first and only erythroid maturation agent approved in the United States, Europe, and Canada for the treatment of anemia in certain blood disorders. REBLOZYL is part of a global collaboration partnership with Bristol Myers Squibb. The Companies co-promote REBLOZYL in North America and are also developing luspatercept for the treatment of anemia in patient populations of MDS, beta-thalassemia, and myelofibrosis. In pulmonary, Acceleron is developing sotatercept for the treatment of pulmonary arterial hypertension (PAH), having recently presented positive topline results of the Phase 2 PULSAR trial. The Company is currently planning multiple Phase 3 trials with the potential to support its long-term vision of establishing sotatercept as a backbone therapy for patients with PAH at all stages of the disease.

 

For more information, please visit www.acceleronpharma.com. Follow Acceleron on Social Media: @AcceleronPharma and LinkedIn.

 

What’s in it for you?

We are seeking a strategic and passionate individual who excels in building brands and teams in order to meet the needs of patients living with challenging health care conditions. Reporting to the Head of US Marketing, the Senior Director for Consumer Marketing will play a critical role in helping to shape the launch of sotatercept in PAH in the US. As a critical member of the Acceleron US commercial organization, the Senior Director for Consumer Marketing will lead the strategic planning and execution of Acceleron’s efforts to activate, educate and support PAH patients through the launch of sotatercept in the US. The Senior Director’s ultimate goal is to ensure that Acceleron’s launch of sotatercept in PAH addresses the unmet needs of US PAH patients and creates values for patients and Acceleron.

 

What will you be doing?

  • Strategic Planning: Develop and execute consumer strategic plan to support the launch of sotatercept in PAH in the United States
  • Brand Planning: Play a critical role in shaping US Brand Strategy, identifying key intervention points for the brand and rallying the organization to deliver against that plan.
  • Communications Platform: Translate deep patient / consumer insights into actionable strategies and a communications platform to activate, educate and support US consumers / patients.  
  • Patient Activation and Media Strategy: Develop and execute patient engagement programs to drive belief and behavior shifts among consumers / patients; Develop and implement innovative media strategies to support brand objectives.
  • Patient Support: In partnership with commercial leadership, shape the US patient support strategy and develop marketing and educational programs to support patients who have been prescribed sotatercept.
  • Consumer Marketing Expertise: Serve as an internal center of excellence on consumer/patient marketing, and partner extensively with various internal functions (Patient Advocacy, US Commercial, US Market Access, Global Brand Team) to ensure that the patient remains at the center of our launch efforts.
  • Leadership: This position will likely oversee direct reports as the team grows, and will help shape Acceleron’s US Commercial Team. As such, this position will help shape Acceleron’s consumer marketing capabilities and will be accountable to build, lead and manage a best-in-class consumer marketing team.
  • Leading on Innovation: Identify and incorporate innovative strategies, programs and tactics that leverage advancements in technology, media and communications to help sotatercept deliver on its brand promise.

What are we looking for?

  • At least At least 8 years of marketing experience in the biotech/pharma/life sciences sector or in consumer health, with at least 5 years of consumer marketing experience. We are open to individuals with deep consumer marketing experience in adjacent categories (ie consumer health).
  • At least 15 years of biotech and commercial experience (marketing, sales, market access, patient advocacy, advertising agency, consumer health) in the biotech/pharma/life sciences sector.
  • MBA or advanced degree preferred
  • Experience is rare/orphan disease is strongly preferred. Experience designing and supporting patient support programs / HUBs strongly preferred.
  • Experience in pulmonary / cardiology is preferred but not required
  • Launch Experience is required, with a strong preference for someone who has developed and executed consumer campaigns
  • Ability to demonstrate leadership on key marketing competencies: Strategic Agility, Influence Without Authority, Decision-Making, Trust and Teamwork, Analytical and Critical Thinking
  • Must demonstrate a true passion for the patient, and is able to rally an organization around meeting the needs of consumers / patients.
  • Strong written and oral communication skills; ability to articulate commercial perspective in a cross-functional setting
  • Ability to work collaboratively with others across all functions and levels within the organization
  • Excellent organizational skills, follow-through and comfort with multi-tasking in a fast-paced environment with changing priorities 

How will you grow with us?

This role will be a critical member of the US launch team for a treatment that could potentially re-shape a disease state with significant unmet need for patients. This person will play a key role in shaping the launch of sotatercept in PAH, a treatment that could become the backbone treatment in PAH and help improve patient outcomes in new ways. As part of an energized, collaborative team, this role will have the opportunity to help shape brand and commercial strategy in the US. We are a small and growing commercial organization, and this role will have the opportunity to grow with the company and help shape our future. If you are interested in joining a dynamic and committed team, and helping us drive change in the interest of patients, then come join Team XLRN!

 

*In compliance with federal law, all persons hired will be required to verify identity and eligibility to work in the United States and complete the required employment eligibility verification document form upon hire.

*Recruiters - please do not send unsolicited resumes to this posting.

FOR IMMEDIATE CONSIDERATION PLEASE SUBMIT YOUR RESUME TO:

www.acceleronpharma.com

 

Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Acceleron’s leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair. Acceleron focuses its research, development, and commercialization efforts in pulmonary and hematologic diseases. In pulmonary, Acceleron is developing sotatercept for the treatment of pulmonary arterial hypertension (PAH), having reported positive topline results of the PULSAR Phase 2 trial. The Company is currently planning multiple Phase 3 trials with the potential to support its long-term vision of establishing sotatercept as a backbone therapy for patients with PAH at all stages of the disease. Acceleron is also investigating the potential of its early-stage pulmonary candidate, ACE-1334, which it plans to advance into a Phase 1b/2 trial in systemic sclerosis-associated interstitial lung disease (SSc-ILD) next year. In hematology, REBLOZYL® (luspatercept-aamt) is the first and only erythroid maturation agent approved in the United States, Europe, and Canada for the treatment of anemia in certain blood disorders. REBLOZYL is part of a global collaboration partnership with Bristol Myers Squibb. The Companies co-promote REBLOZYL in the United States and are also developing luspatercept for the treatment of anemia in patient populations of myelodysplastic syndromes, beta-thalassemia, and myelofibrosis. For more information, please visit www.acceleronpharma.com. Follow Acceleron on Social Media: @AcceleronPharma and LinkedIn.